First Trust Advisors
JNCE

First Trust Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

First Trust Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-72,807
Closed -$495K – 2676
2021
Q2 		$495K Buy
72,807
+13,103
+22% +$109K ﹤0.01% 2283
2021
Q1 		$613K Buy
59,704
+18,246
+44% +$200K ﹤0.01% 2149
2020
Q4 		$290K Sell
41,458
-1,616
-4% -$12.6K ﹤0.01% 2228
2020
Q3 		$351K Buy
+43,074
New +$267K ﹤0.01% 2127

Other funds holding JNCE

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

First Trust Advisors's JNCE Position: Q3 2021 in Review

First Trust Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 72,807 shares — an estimated $495K sold.

First Trust Advisors first reported a position in JNCE in Q3 2020 and held it in 4 quarters. The position peaked at $613K in Q1 2021. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

  • First Trust Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • First Trust Advisors sold 72,807 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $495K.
  • First Trust Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • First Trust Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $613K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on First Trust Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.